zurück

Nirmatrelvir / ritonavir (COVID-19, patients not requiring supplemental oxygen, with increased risk of progressing to severe COVID-19)

 

Subject:

  • Active Substance: Nirmatrelvir / ritonavir
  • Name: Paxlovid®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: Pfizer Pharma GmbH

 

Time table:

  • Start: 01.07.2022
  • Final decision by G-BA: 15.12.2022

 

Final decision:

  • HInt for a considerable additional benefit